NeuroPace (NPCE) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NPCE NeuroPace

Watchlist

12.010
-0.410-3.30%

Close Jan 8 16:00 ET

12.510
+0.500+4.16%

Post 16:06 ET

358.48MMarket Cap-12.26P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsJan 9 05:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Tecan Group AG (OtherTCHBF) and Avidity Biosciences (RNA)
TipRanksJan 9 04:50 ET · Ratings
NeuroPace Narrows FY24 Revenue View to $79.4M-$79.9M From $78M-$80M
TipRanksJan 8 16:15 ET
NeuroPace, Inc. Reports Preliminary Q4 2024 Revenue Projections and Announces Scott Huennekens as New Board Member
Quiver QuantitativeJan 8 16:13 ET
NeuroPace: NAUTILUS Pivotal Trial Is on Track to Complete Required 1-Yr Follow-Up of Subjects in March >NPCE
Dow JonesJan 8 16:10 ET
NeuroPace Sees Data Lock and Subsequent Trial Data Analysis Commencing in 2Q
Dow JonesJan 8 16:10 ET

Comments

Moomoo AI

Mar 7, 2024 13:13

Analysts show improved sentiment towards NeuroPace, upgrading their numbers and reducing losses per share. A wide gap in price targets implies a broad range of business scenarios. NeuroPace is expected to outpace industry growth.

Earnings Update: Here's Why Analysts Just Lifted Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$16.00

Moomoo AI

Feb 8, 2024 14:14

NeuroPace's high P/S ratio is justified by expected strong revenue growth, outpacing the Medical Equipment industry. Shareholders are optimistic about future revenues, holding onto their shares.

NeuroPace, Inc.'s (NASDAQ:NPCE) P/S Is Still On The Mark Following 34% Share Price Bounce

Analysts Notebook

Apr 6, 2022 06:01

Columns Top upgrades and downgrades on 4/6

Upgrades
• $Banc of California (BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers (CFR.US)$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger (GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc (INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp (PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...

Rama Krishna Gonga

Sep 22, 2021 06:11

$NeuroPace (NPCE.US)$ So the price action on this really looks like the bull run will take it up.
It recently ipo'd so theres a ton of volume surging through this.
The macd doesnt look to good but it could continue to churn upward.
The vortex5 its about to cross the .75 line and would that be the buy signal?
Will we see institutional buying at these levels?

DisneyDad

Apr 21, 2021 19:50

$NeuroPace (NPCE.US)$ trying to enter below 15 if lucky
IPO’ed today

Heat List

Overall

No Data